Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A mutator phenotype in cancer.

L A Loeb1

  • 1Departments of Pathology and Biochemistry, The Joseph Gottstein Memorial Cancer Research Laboratory, University of Washington, Seattle, WA 98195-7705, USA. laloeb@u.washington.edu

Cancer Research
|April 20, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Werner Syndrome, aging and cancer.

Genome dynamics·2008
Same author

Mutations in human DNA polymerase eta motif II alter bypass of DNA lesions.

The EMBO journal·2001
Same author

In vivo mutagenesis by Escherichia coli DNA polymerase I. Ile(709) in motif A functions in base selection.

The Journal of biological chemistry·2001
Same author

Getting a grip on how DNA polymerases function.

Nature structural biology·2001
Same author

The contribution of endogenous sources of DNA damage to the multiple mutations in cancer.

Mutation research·2001
Same author

Enzymatic properties of rat DNA polymerase beta mutants obtained by randomized mutagenesis.

Nucleic acids research·2001
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
Same journal

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

Cancer research·2026
Same journal

Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

Cancer research·2026
See all related articles

Cancer cells often exhibit a mutator phenotype, accumulating thousands of mutations due to faulty genetic stability maintenance. This early-stage defect may drive tumor progression and influence treatment resistance.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Tumor progression is hypothesized to involve a mutator phenotype.
  • This phenotype arises from mutations in genes responsible for maintaining genetic stability.
  • Recent evidence supports the existence of a mutator phenotype in cancer.

Purpose of the Study:

  • To review the concept of a mutator phenotype in cancer.
  • To present evidence of extensive mutations in cancer cells.
  • To explore genes involved in genetic stability and their mutation status in cancer.
  • To investigate the timing of the mutator phenotype during tumor progression.
  • To discuss implications for cancer treatment and prevention.

Main Methods:

  • Review of existing literature and experimental evidence.

Related Experiment Videos

  • Analysis of data on chromosomal and DNA mutations in human cancer cells.
  • Identification and examination of potential target genes for genetic stability maintenance.
  • Assessment of mutation rates and their correlation with tumor progression and drug resistance.

    • Main Results:

    • Human cancer cells frequently contain thousands of mutations.
    • Evidence suggests a mutator phenotype is a common feature of cancer cells.
    • The timing of the mutator phenotype, particularly its early occurrence, is under investigation.
    • Mutations may confer resistance to chemotherapeutic agents.

    Conclusions:

    • A mutator phenotype, characterized by numerous mutations, is strongly supported by experimental evidence in cancer.
    • Understanding the genetic basis and timing of this phenotype is crucial.
    • Targeting genes involved in genetic stability maintenance could offer therapeutic strategies.
    • Reducing mutation rates early in carcinogenesis may represent a cancer prevention by delay approach.